{"id":58535,"date":"2026-03-02T13:40:10","date_gmt":"2026-03-02T05:40:10","guid":{"rendered":"https:\/\/flcube.com\/?p=58535"},"modified":"2026-03-02T13:40:11","modified_gmt":"2026-03-02T05:40:11","slug":"hangyu-pharmas-sosimerasib-wins-nmpa-approval-first-kras-g12c-inhibitor-for-post-therapy-nsclc-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58535","title":{"rendered":"Hangyu Pharma&#8217;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China"},"content":{"rendered":"\n<p><strong>Zhejiang Hangyu Pharmaceutical Co., Ltd.<\/strong>, a subsidiary of <strong>Jemincare<\/strong>, announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>sosimerasib<\/strong>, a <strong>Category\u202f1 innovative KRAS G12C inhibitor<\/strong>, for the treatment of <strong>adult patients with advanced non\u2011small cell lung cancer (NSCLC)<\/strong> harboring the <strong>KRAS G12C mutation<\/strong> who have received <strong>at least one prior systemic therapy<\/strong>. The approval marks a significant milestone in <strong>targeted therapy for KRAS\u2011driven cancers<\/strong>, a historically &#8220;undruggable&#8221; oncogene.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Zhejiang Hangyu Pharmaceutical Co., Ltd. (Jemincare subsidiary)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Sosimerasib<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Category\u202f1 innovative drug; KRAS G12C inhibitor<\/td><\/tr><tr><td><strong>Regulatory Action<\/strong><\/td><td>NMPA marketing approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced NSCLC with KRAS G12C mutation (\u2265\u202f1 prior systemic therapy)<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Two tablets once daily<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-evidence-key-registration-trial\">Clinical Evidence \u2013 Key Registration Trial<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Sosimerasib Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Objective Response Rate (ORR)<\/strong><\/td><td><strong>55.2%<\/strong><\/td><\/tr><tr><td><strong>12\u2011Month Overall Survival Rate<\/strong><\/td><td><strong>60.4%<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Advanced NSCLC, KRAS G12C\u2011mutant, post\u2011prior therapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS &#8220;Undruggable&#8221; Target Cracked:<\/strong> Sosimerasib joins <strong>sotorasib (Amgen)<\/strong> and <strong>adagrasib (Mirati\/BMS)<\/strong> as approved KRAS G12C inhibitors, validating <strong>direct KRAS targeting<\/strong> as a viable therapeutic strategy.<\/li>\n\n\n\n<li><strong>China Market First:<\/strong> As a <strong>domestically developed Category\u202f1 drug<\/strong>, sosimerasib may secure <strong>formulary preference<\/strong> and <strong>reimbursement advantages<\/strong> vs. imported competitors in China&#8217;s healthcare procurement system.<\/li>\n\n\n\n<li><strong>Adherence Optimization:<\/strong> The <strong>&#8220;two tablets once daily&#8221;<\/strong> dosing simplifies administration vs. some competitor regimens, potentially improving <strong>patient compliance<\/strong> and <strong>real\u2011world effectiveness<\/strong>.<\/li>\n\n\n\n<li><strong>Pipeline Expansion:<\/strong> <strong>FAK inhibitor combination<\/strong> development for <strong>first\u2011line therapy<\/strong> addresses <strong>single\u2011agent resistance mechanisms<\/strong>, positioning Hangyu Pharma for <strong>label expansion<\/strong> and <strong>earlier\u2011stage market entry<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>Company<\/th><th>Status<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Sotorasib<\/strong><\/td><td>Amgen<\/td><td>Approved (US, China)<\/td><td>First\u2011to\u2011market KRAS G12C inhibitor<\/td><\/tr><tr><td><strong>Adagrasib<\/strong><\/td><td>Mirati\/BMS<\/td><td>Approved (US, China)<\/td><td>Potentially superior CNS penetration<\/td><\/tr><tr><td><strong>Sosimerasib<\/strong><\/td><td>Hangyu Pharma\/Jemincare<\/td><td><strong>Approved (China)<\/strong><\/td><td>Domestic development; simplified BID dosing; FAK combo pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>KRAS G12C Prevalence<\/strong><\/td><td>~\u202f14% of NSCLC adenocarcinomas in China; ~\u202f25,000\u201130,000 annual eligible patients<\/td><\/tr><tr><td><strong>Post\u2011Chemo\/IO Setting<\/strong><\/td><td>Limited effective options after progression on platinum\u2011based chemotherapy and PD\u20111 inhibitors; KRAS G12C inhibitors address urgent unmet need<\/td><\/tr><tr><td><strong>Domestic Innovation Premium<\/strong><\/td><td>Category\u202f1 status supports pricing power and hospital listing priority<\/td><\/tr><tr><td><strong>Combination Strategy<\/strong><\/td><td>FAK inhibition addresses compensatory signaling driving resistance; first\u2011line combo could expand addressable market 3\u20114x<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercial launch timelines, market share capture, and FAK combination development outcomes. Actual results may differ due to risks including competitive pricing pressure, reimbursement negotiation delays, and combination trial enrollment challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China&#8217;s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58537,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4632,1699,15],"class_list":["post-58535","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hangyu-pharmaceutical","tag-jemincare","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hangyu Pharma&#039;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China&#039;s National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically &quot;undruggable&quot; oncogene.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58535\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hangyu Pharma&#039;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China\" \/>\n<meta property=\"og:description\" content=\"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China&#039;s National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically &quot;undruggable&quot; oncogene.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58535\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-02T05:40:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-02T05:40:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hangyu Pharma&#8217;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China\",\"datePublished\":\"2026-03-02T05:40:10+00:00\",\"dateModified\":\"2026-03-02T05:40:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0204.webp\",\"keywords\":[\"Hangyu Pharmaceutical\",\"Jemincare\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58535#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58535\",\"name\":\"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0204.webp\",\"datePublished\":\"2026-03-02T05:40:10+00:00\",\"dateModified\":\"2026-03-02T05:40:11+00:00\",\"description\":\"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China's National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically \\\"undruggable\\\" oncogene.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58535\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0204.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0204.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58535#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hangyu Pharma&#8217;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China - Insight, China&#039;s Pharmaceutical Industry","description":"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China's National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically \"undruggable\" oncogene.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58535","og_locale":"en_US","og_type":"article","og_title":"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China","og_description":"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China's National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically \"undruggable\" oncogene.","og_url":"https:\/\/flcube.com\/?p=58535","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-02T05:40:10+00:00","article_modified_time":"2026-03-02T05:40:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58535#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58535"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hangyu Pharma&#8217;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China","datePublished":"2026-03-02T05:40:10+00:00","dateModified":"2026-03-02T05:40:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58535"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58535#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","keywords":["Hangyu Pharmaceutical","Jemincare","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58535#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58535","url":"https:\/\/flcube.com\/?p=58535","name":"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58535#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58535#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","datePublished":"2026-03-02T05:40:10+00:00","dateModified":"2026-03-02T05:40:11+00:00","description":"Zhejiang Hangyu Pharmaceutical Co., Ltd., a subsidiary of Jemincare, announced that China's National Medical Products Administration (NMPA) has approved sosimerasib, a Category\u202f1 innovative KRAS G12C inhibitor, for the treatment of adult patients with advanced non\u2011small cell lung cancer (NSCLC) harboring the KRAS G12C mutation who have received at least one prior systemic therapy. The approval marks a significant milestone in targeted therapy for KRAS\u2011driven cancers, a historically \"undruggable\" oncogene.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58535#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58535"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58535#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","width":1080,"height":608,"caption":"Hangyu Pharma's Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58535#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hangyu Pharma&#8217;s Sosimerasib Wins NMPA Approval \u2013 First KRAS G12C Inhibitor for Post\u2011Therapy NSCLC in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0204.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58535"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58535\/revisions"}],"predecessor-version":[{"id":58538,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58535\/revisions\/58538"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58537"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58535"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58535"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}